Fisetin: The Senolytic Flavonoid, and What the Research Actually Shows

Fisetin is the strawberry compound that the longevity world adopted as a "senolytic," a supplement that supposedly clears out the aged, dysfunctional cells thought to drive aging. It is a genuinely interesting molecule with striking preclinical data, and it is also the perfect case study in the gap between an exciting mouse experiment and a proven human supplement. The honest one-line summary, which most marketing skips, is this: the impressive results are in mice and cells, the most rigorous mouse study failed to replicate the headline finding, and there is not a single completed human trial showing it does anything for lifespan or healthspan. This guide explains what fisetin is, what a senolytic actually means, where the evidence stands, and why poor absorption complicates the whole story.

What fisetin actually is

Fisetin is a flavonol, a subtype of the plant polyphenols, and structurally it is a close relative of quercetin. It is a plant pigment found in a range of fruits and vegetables, with strawberries by far the richest common source, followed at much lower levels by apples, persimmons, and grapes. The amounts in food are tiny next to supplement doses. Average dietary fisetin intake is estimated at well under a milligram a day, while supplement capsules typically contain 100 to 500 mg, and the longevity protocols push toward 1,000 to 1,500 mg for two days at a time. In other words, the "senolytic" doses people take are thousands of times more than you could ever eat, which is worth stating plainly: you cannot eat your way to a senolytic dose of fisetin.

Senescent cells, and why fisetin is trending

Fisetin went from "an antioxidant in strawberries" to "longevity supplement" almost entirely on the strength of preclinical findings that it acts as a senolytic. To understand the appeal, you need the concept of senescent cells, sometimes called zombie cells. These are older cells that have stopped dividing but refuse to die, and instead linger and secrete a cocktail of inflammatory signals (known as the senescence-associated secretory phenotype). They accumulate with age and are thought to contribute to age-related inflammation and tissue dysfunction. A senolytic is a compound that selectively pushes these cells to finally die off. When a 2018 mouse study reported that fisetin did exactly that and extended lifespan, the longevity community embraced it, and the supplement market followed.

The animal evidence (genuinely mixed)

The famous study is Yousefzadeh and colleagues, 2018, in EBioMedicine, from groups at the Mayo Clinic and University of Minnesota. In aged mice fed high-dose fisetin starting late in life, the treatment reduced markers of cellular senescence across tissues and extended median and maximum lifespan, with secondary coverage commonly citing roughly a 10 percent extension (treat that figure as approximate rather than a precise quote). In human tissue samples studied in a dish, fisetin also reduced senescent cells. That is a striking result, and it is the foundation of fisetin's reputation.

Here is the part the marketing leaves out. The U.S. National Institute on Aging runs the Interventions Testing Program, the gold-standard, multi-site, rigorously controlled program for testing whether compounds extend mouse lifespan. When the ITP tested fisetin in genetically diverse mice, published in 2023, it did not significantly extend lifespan in either sex. So the headline 2018 result has not been cleanly replicated in the most stringent independent model. The animal evidence itself is mixed, and an honest account of fisetin has to include that, because supplement marketing almost never does.

The human evidence (essentially none, yet)

This is the crux. There are no published human randomized trials showing fisetin extends lifespan, healthspan, or reverses aging. The human work that exists is early-phase, mostly ongoing, and largely unpublished. The trials people point to, run mainly at the Mayo Clinic, are studying fisetin for frailty and inflammation in older adults (the AFFIRM and AFFIRM-LITE studies), using the intermittent high-dose schedule. As of this writing those trials are still running, with completion estimated around late 2026, and have not reported results. Earlier pilot studies in COVID-19 and an osteoarthritis trial are completed but inconclusive or unpublished. The honest headline could not be simpler: exciting mouse and cell data, human outcomes not yet proven. Fisetin belongs in the same "investigational" bucket as other emerging longevity compounds like NMN, urolithin A, and spermidine, which we cover with the same caution.

The "hit-and-run" protocol

Because senolytics theoretically need only a brief, high-peak exposure to push senescent cells over the edge, the longevity community favors intermittent high pulses over low daily dosing, the so-called hit-and-run approach. The popularized regimen is roughly 20 mg per kg of bodyweight for two consecutive days, repeated about monthly, which for a 70 kg adult works out to around 1,400 mg a day for those two days. That dose mirrors the Mayo frailty-trial protocol, which is at least internally consistent, but the key caveat is that those trials have not reported outcomes, so the schedule is extrapolated from animal dosing and trial design, not validated by human efficacy data. Low daily dosing has even less evidence behind it for senolysis. Anyone seriously considering high-dose pulses should do it with a clinician, not a podcast.

Why absorption is the catch

Fisetin's bioavailability is poor, and this undercuts the simple assumption that swallowing a capsule reproduces a mouse-study exposure. It is barely water-soluble, heavily broken down and conjugated in the body, pumped back out of cells, and rapidly metabolized, with the free-fisetin half-life after intravenous dosing measured in minutes. Much of an oral dose never reaches your tissues as active fisetin. Manufacturers have responded with enhanced-absorption formulations (liposomal, micellar, and a fenugreek-galactomannan hydrogel form that one human study found raised blood levels many-fold). The honest caveat is that higher blood levels are not the same as proven clinical benefit, and better absorption also changes the safety calculus, so an "enhanced" label is not automatically a better product.

Safety and who should be cautious

In the limited human pilots and the animal work, fisetin appears generally well tolerated short term, with mild effects like GI upset, headache, or fatigue reported. The honest uncertainties:

• Long-term and high-dose safety is unknown. There is no long-term human safety data at the high pulsed doses used in protocols.
• Blood thinners and drug interactions. As a flavonoid that inhibits the CYP2C9 enzyme (and others), fisetin may potentiate warfarin and other anticoagulants and antiplatelets, and could affect the levels of drugs with a narrow therapeutic window. This is mechanistic, but a reasonable caution.
• Pregnancy and breastfeeding. Avoid concentrated supplements; there is no fetal or infant safety data. Dietary amounts from food are fine.

Frequently asked questions

What is a senolytic?

A senolytic is a compound that selectively kills senescent cells, which are older cells that have stopped dividing but resist dying and leak inflammatory signals. The theory is that clearing them reduces age-related dysfunction. Fisetin is studied as a natural senolytic, but senolytic describes a mechanism seen mainly in cells and animals, not a proven human anti-aging effect.

Does fisetin extend lifespan in humans?

No, that has not been shown. Lifespan extension was reported in aged mice in 2018, and even that result was not replicated in the most rigorous independent mouse program in 2023. There are zero completed human trials showing fisetin extends lifespan or healthspan. Human frailty trials are still running and have not reported results.

What is the hit-and-run protocol, and is it validated?

It is intermittent high-dose fisetin, commonly cited as about 20 mg per kg of bodyweight for two consecutive days, repeated periodically, on the theory that senescent cells only need a brief high exposure to be cleared. That dose comes from animal data and unfinished clinical-trial protocols; it is not validated by published human outcome data. Anyone considering it should involve a clinician.

Is fisetin well absorbed?

No, its bioavailability is poor. Fisetin is barely water-soluble, is rapidly metabolized (free-fisetin half-life is measured in minutes after intravenous dosing), and is heavily conjugated and pumped back out in the gut. Enhanced forms such as liposomal or hydrogel preparations raise blood levels, but higher absorption has not been shown to translate into clinical benefit.

Fisetin vs quercetin: what is the difference?

Both are flavonols with similar structures; quercetin has more hydroxyl groups and is slightly more water-soluble. In laboratory senolytic screens, fisetin was the more potent single-agent senolytic and appears active in tissues like fat where quercetin is weaker, while quercetin is usually paired with a drug to act as a senolytic. Both have poor bioavailability and unproven human anti-aging effects.

Is fisetin safe?

Short term and at studied doses, it appears generally well tolerated, with mild GI upset or headache possible. But long-term and high-dose safety is unknown. Because it is a flavonoid that inhibits the CYP2C9 enzyme and other drug-metabolizing enzymes, it may interact with blood thinners and other medications, so people on prescriptions, and anyone pregnant or breastfeeding, should avoid it or consult a clinician.

The bottom line

Fisetin is a genuinely interesting strawberry-derived flavonol with real preclinical senolytic data, and it is also a textbook example of why "promising in mice" is not the same as "works in people." The 2018 lifespan result was striking, but it was in mice, it was not replicated in the most rigorous independent program, fisetin is poorly absorbed, and there is not a single completed human longevity or healthspan trial. The most honest way to describe it is as a polyphenol being studied for healthy aging, still investigational in humans, full stop. If the longevity space interests you, fisetin is worth watching as those frailty trials report out, but it deserves the same evidence-first skepticism we bring to the whole category in the longevity blueprint.